CERUMENEX
LOE ApproachingPeptidetrolamine polypeptide oleate condensate
NDAOTICSOLUTION/DROPS
Approved
Jun 1958
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 4h ago · AI intelligence enriched 9h ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CERUMENEX is a trolamine polypeptide oleate condensate solution administered as otic drops for cerumen (earwax) removal. It is a ceruminolytic agent that softens and facilitates the mechanical removal of impacted cerumen from the ear canal. The product has been in use since 1958 and represents a classic topical therapeutic approach to a common primary care issue.
LOE Approaching
With LOE approaching on a legacy otic product facing moderate competitive pressure (30%), commercial teams are likely small and focused on defensive retention rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
CERUMENEX offers limited career growth opportunities given its LOE-approaching lifecycle and zero linked job openings. Roles in this space are typically maintenance-focused, emphasizing compliance, cost management, and stakeholder retention rather than market expansion.
Brand ManagerField Sales Representative
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.